GRAIL (GRAL) Q2 2026 earnings review
Strong Volume Growth Clouded by Accelerating Losses and FDA Review Extension
GRAIL posted a solid 26% YoY revenue increase to $44.7M in Q2, driven by a 35% jump in Galleri test volumes. However, bottom-line metrics are moving in the wrong direction: Adjusted EBITDA loss widened by 15% to $90.3M, signaling accelerating cash burn as the company scales. The most critical update is regulatory: management now anticipates an FDA Advisory Committee (AdCom) in the fall. During the previous quarter, management noted an AdCom could extend the FDA review timeline from ~180 days to ~320 days, introducing a significant delay to potential broad reimbursement.
🐂 Bull Case
Galleri test volumes exceeded 61,000 for the quarter. Partnerships like the new coverage agreement with Priority Health demonstrate ongoing traction in the self-insured employer and commercial payer markets.
Detailed presentations at ASCO for the 140,000-participant NHS-Galleri and 35,000-participant PATHFINDER 2 trials reaffirmed Galleri's ability to significantly shift cancer diagnoses to earlier stages and quadruple overall cancer detection.
🐻 Bear Case
Despite a 34% increase in Adjusted Gross Profit, Adjusted EBITDA loss expanded 15% YoY to $90.3M. Operating expenses are vastly outstripping gross profit dollars, raising concerns about the path to profitability.
The confirmation of a fall FDA Advisory Committee means a likely delay in PMA approval. This pushes back the timeline for unlocking CMS coverage, keeping GRAIL dependent on self-pay and limited employer channels for longer.
⚖️ Verdict: ⚪
Neutral. Commercial execution remains strong and the $110M Samsung financing secures the balance sheet. However, the widening EBITDA loss and the extended FDA review timeline via the AdCom are near-term headwinds that dampen the growth narrative.
Key Themes
FDA Advisory Committee Confirmed
Management confirmed the FDA will hold an Advisory Committee in the fall to review the Galleri PMA application. In Q1, management warned that an AdCom would stretch the standard ~180-day review to roughly ~320 days. This materialized risk means the ultimate catalyst—FDA approval unlocking Medicare reimbursement pathways—is pushed further out.
Adjusted EBITDA Loss Accelerating
The gap between gross profit and operating expenses is widening. While Adjusted Gross Profit grew $5.4M YoY, Adjusted EBITDA loss worsened by $11.9M to reach $90.3M. This suggests that expanding the sales force (from ~90 to 120 territories) and increasing marketing spend are driving significant cost inflation.
Test Volume Growth Decelerating
While still robust, Galleri test volume growth is decelerating. Volume grew 50% YoY in Q1 2026, but the growth rate slowed to 35% in Q2 2026 (61,000+ tests). Monitoring whether new EHR integrations (like Epic) can re-accelerate this metric in the second half of the year is critical.
Clinical Validation Reinforced at ASCO
GRAIL continues to leverage its massive clinical datasets to drive physician adoption. The NHS-Galleri data presented at ASCO showed a 22-26% reduction in Stage IV diagnoses for 12 aggressive cancers, while PATHFINDER 2 data demonstrated a 6.5x increase in cancer detection compared to standard screenings. This data is the primary tool for the newly expanded sales force.
Commercial Payer Expansion
The company is successfully opening new reimbursement channels ahead of FDA approval. A new collaboration with Priority Health will make Galleri available to its self-insured employer groups in Michigan, building on Priority Health's earlier inclusion of Galleri in its Medicare Advantage plans.
Other KPIs
Accelerating. Adjusted gross profit increased 34% YoY, outpacing the 26% total revenue growth. This indicates improving lab efficiencies and better fixed-cost leverage on higher sample volumes, insulating the core unit economics from potential ASP (Average Selling Price) pressures.
Stable. The balance sheet was fortified by the completion of a $110 million equity financing with Samsung. Despite the high quarterly cash burn, this significant reserve allows GRAIL to absorb the extended FDA review timeline without immediate dilutive financing risk.
Guidance
Management expects an FDA Advisory Committee meeting in the fall of 2026 to review the PMA application. This formally updates the regulatory timeline, pushing potential approval expectations deeper into 2027.
Key Questions
AdCom Preparation
With the FDA Advisory Committee now confirmed for the fall, what specific data points or topics do you anticipate the committee focusing on most heavily, particularly concerning the NHS-Galleri primary endpoint miss?
EBITDA Loss Drivers
Adjusted EBITDA loss expanded 15% this quarter despite strong gross margin improvements. How much of this OpEx increase is tied to the recent 120-territory sales force expansion, and when do you expect those new reps to reach full productivity and drive operating leverage?
ASP and Volume Dynamics
Test volume growth decelerated sequentially from 50% in Q1 to 35% in Q2. Is this a function of seasonality, or are you seeing changes in the uptake velocity from your digital health partners? Furthermore, how did Average Selling Price (ASP) trend this quarter amidst ongoing discount programs?